Aktuellt
SENASTE
Redeye initiates coverage of Pila Pharma, a phase II company developing a novel approach to type 2 diabetes treatment with XEN-D0501, a TRPV1 antagonist. We see little of this potential priced into the share and believe the current share price levels represent an opportunity ahead of the catalyst of the phase IIb readout.
LÄS MER
